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A Case of Trimebutine-Induced
Anaphylaxis
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ABSTRACT
Trimebutine maleate [2-dimethylamino-2-phenylbutyl 3,4,5-trimethoxybenzoic acid] has been demonstrated to
be active for relieving abdominal pain and it is widely used for patients with irritable bowel syndrome. Adverse
drug reactions are mostly mild and well-tolerated. To our knowledge, only two cases of trimebutine induced hy-
persensitivity have been reported, and both were delayed type reactions. Here, we report the first case of trime-
butine maleate-induced anaphylaxis.
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INTRODUCTION
Trimebutine has been commonly used in many coun-
tries for a long time since 1969.1 It is taken orally to
relieve gastroesophageal reflux disease, gastric ulcer,
and irritable bowel syndrome.2-6 It is metabolized into
nor-trimebutine, and it can regulate colonic motility
through both anti-muscarinic and weak opioid agonis-
tic properties.1 Since it is commonly used as an over-
the-counter drug, some adverse drug reactions such
as diarrhea, constipation, vomiting, thirst, tachycar-
dia, headache, fatigue, and elevated serum liver trans-
aminase have been reported.2 To our knowledge,
trimebutine maleate-induced hypersensitivity reac-
tions have not been reported except for two cases of
type IV hypersensitivity reaction including allergic
dermatitis and delayed-type urticaria by topical use of
trimebutine.7,8 However, there have been no reported
cases of trimebutine maleate-induced anaphylaxis un-
til now.
CASE REPORT
A 65-year-old woman experienced sudden onset of se-
vere generalized erythema and dyspnea after taking
trimebutine maleate, cefaclor, and aceclofenac.
She had no history of allergic diseases or other ad-
verse drug reactions. She had been taking telmisar-
tan, hydrochlorothiazide, rosuvastatin calcium, am-
lodipine, and metformin hydrochloride safely for the
past 10 years.
Routine laboratory tests revealed no remarkable
abnormality, and serum total IgE level was within
normal range. A skin test was done with the original
drug, trimebutine maleate, which did not contain any
preservatives. While the skin prick test was negative,
the intradermal test was positive at a 1 mgml (10 × 9
mm wheal and 24 × 22 mm flare). Serum specific IgE
to cefaclor was not detected by the ImmunoCAP sys-
tem (Uppsala, Sweden).
In order to confirm the culprit drug, oral challenge
tests were done. First, we tested trimebutine maleate.
Initial blood pressure was 12080 mmHg. One hour
after taking 100 mg of trimebutine maleate, the pa-
tient had generalized erythema with pruritus. She
complained of dizziness as her blood pressure sud-
denly dropped to 8050 mmHg at 90 minutes after
trimebutine intake. Her symptoms were relieved with
shock positioning and a rapid saline drip. Administra-
tion of intravenous dexamethasone and chlorpheni-
ramine followed the drip. Two weeks after the initial
oral challenge test with trimebutine maleate, we did
oral challenge tests with aspirin up to 750 mg and ce-
faclor up to 625 mg separately. Neither aspirin nor ce-
faclor provoked any symptoms in the patient upon
oral challenge test. Aceclofenac (100 mg) was also re-
administered without any adverse reaction and has
been used by the patient as a safe analgesic.
With these provocation tests, we confirmed
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trimebutine-induced anaphylaxis in this case.
DISCUSSION
Trimebutine [2-dimethylamino-2-phenylbutyl 3,4,5-
trimethoxybenzoic acid] is an enkephalin analogue
and stimulates the enkephalin receptor in the enteric
nerve system by modulating visceral sensitivity and
normalizing altered bowel movement.1,2 The actions
of trimebutine on the gastrointestinal tract are medi-
ated through the agonist effect on the peripheral opi-
ate receptors and though the release of gastrointesti-
nal peptides such as motilin and though the modula-
tion of the release of other peptides including vasoac-
tive intestinal peptide, gastrin, and glucagon.2 When
given orally, trimebutine is metabolized in the liver to
nor-trimebutine.1 In the Korean domestic market,
trimebutine maleate is widely distributed with 83 dif-
ferent brand names including 32 multiple-ingredient
preparations containing trimebutine as well as 51
single-ingredient preparations. Moreover, 40% of
them are sold as over-the-counter drugs.
Drug-induced anaphylaxis has been frequently as-
sociated with beta-lactam antibiotics, aspirin, non-
steroidal antiinflammatory drugs (NSAIDs), radio-
contrast media, muscle relaxants, and chemothera-
peutic agents.9,10 Since cefaclor and NSAIDs are
widely used in practice and frequently reported as
causative agents of drug-induced anaphylaxis, these
two drugs were initially suspected as the culprit drug
inducing the anaphylaxis in this patient. However,
against our expectation, trimebutine was confirmed
as the causative agent of anaphylaxis by oral provoca-
tion test. To prevent anaphylaxis, the patient was edu-
cated to avoid trimebutine, but she was allowed to
use cefaclor and NSAIDs. This case emphasizes the
importance of the provocation test in drug allergies
and suggests not to depend upon assumptions when
determining causative drugs.
To our knowledge, this is the first case of trime-
butine maleate-induced anaphylaxis that has been re-
ported. Although there were two cases of
trimebutine-induced allergic skin reactions by topical
use, this case is not only the first case of anaphylaxis
by trimebutine, but also the first report of an allergic
reaction after the oral administration of trimebutine
worldwide. We confirmed trimebutine maleate as the
causative agent of anaphylaxis but could not show the
existence of a specific IgE to trimebutine since the
patient did not return to the clinic.
In conclusion, we report that trimebutine, a com-
monly used over-the-counter drug, can induce a se-
vere anaphylactic reaction.
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